COMMUNIQUÉS West-GlobeNewswire

-
Arcturus Therapeutics Hosts Ribbon Cutting Ceremony for its Research and Development Facility
05/11/2018 -
Dova Pharmaceuticals Announces FDA Acceptance of Supplemental New Drug Application for DOPTELET® (avatrombopag) for the Treatment of Chronic Immune Thrombocytopenia (ITP)
05/11/2018 -
Clearside Biomedical Announces SAPPHIRE Phase 3 Study of Combination Therapy in Retinal Vein Occlusion Did Not Meet Its Primary Endpoint
05/11/2018 -
AnaptysBio to Participate in Upcoming Investor Conferences
05/11/2018 -
Flexion Therapeutics Announces Product-Specific J Code (J3304) for ZILRETTA® (triamcinolone acetonide extended-release injectable suspension) Effective January 1, 2019
05/11/2018 -
Alpha Pro Tech, Ltd. Announces Financial Results for the Third Quarter and Nine Months Ended September 30, 2018
05/11/2018 -
Invitation to investor meeting on November 8, 2018
05/11/2018 -
Quotient Limited Reports Positive MosaiQ Audit Results and Instrument CE Mark with Second Quarter Fiscal 2019 Financial Results
05/11/2018 -
Capital Senior Living Corporation to Present at the Stephens NY Investment Conference on Wednesday, November 7, 2018
05/11/2018 -
Arrayit Corporation Announces Brands Expansion of Proprietary Finger Stick Allergy Testing
05/11/2018 -
Enzymatica AB: Bulletin from Extraordinary General Meeting in Enzymatica AB (publ)
05/11/2018 -
William Demant Holding A/S: Financial calendar 2019
05/11/2018 -
Biohit Oyj B-shares Subscribed with Stock Options I 2013
05/11/2018 -
Exalenz to Present Positive Clinical Data for the Breath ID® 13C-Methacetin Breath Test System at the Liver Meeting® 2018
05/11/2018 -
Novartis R&D update highlights industry leading development pipeline including potential blockbusters and advanced therapy platforms
05/11/2018 -
ERYTECH to Host KOL Breakfast Symposium with Audio Webcast on November 7, 2018
05/11/2018 -
ERYTECH tiendra un colloque avec des leaders d’opinion retransmis en direct le 7 novembre 2018
05/11/2018 -
Semaglutide demonstrated superior improvements in glycaemic control vs placebo in adults with type 2 diabetes
05/11/2018 -
Victoza® (liraglutide 1.8 mg) provided superior HbA1c reductions in adults with type 2 diabetes compared to continued sitagliptin treatment
05/11/2018
Pages